Pharmaceuticals

This report will provide:

• An overview of the market for genetourinary drugs, with details on drugs separated into segments for each of the major diseases
• Analyses of global market trends, with data from 2010, estimates for 2011, and projections of compound annual growth rates (CAGRs) through 2016
• Discussion of each drug, current and pipeline, the nature of the drug, its mechanism of action, and its FDA approval status
• Delineation of disease categories and their markets, including benign prostatic hypertrophy (BPH), erectile dysfunction, urinary incontinence and overactive bladder, hormonal contraceptives. and infection
• Identification of drug patents and clinical trials
• Comprehensive company profiles of major players in the industry.

Target Date: June 2012 Report ID: PHM115A Report Author: Jackson Highsmith Price: $4,850.00

This report will provide:

• An overview of human applications both marketed and in the development of antifungal technologies
• Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Examinations of factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance, and changes in consumerism, such as a greater demand for over-the-counter (OTC) medications and/or natural and alternative remedies
• Discussion of the industry structure, including market shares
• Comprehensive company profiles of major players.

Target Date: June 2012 Report ID: PHM029D Report Author: Mary Anne Crandall Price: $4,850.00

This report will provide:

• An overview of the global market for infertility treatment drugs and technologies, with a focus on signs and symptoms, treatment and management, and current reproductive technologies, techniques, and devices
• Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Discussion of infertility drugs on the market for male infertility and female infertility
• Examination of drivers and barriers in the infertility therapeutics market, including patents, government regulations, reimbursement policies, and unmet needs
• Data regarding infertility drugs sales by indication, including ovulation disorders, Fallopian tube abnormalities, endometriosis, cervical narrowing/blockage, and uterine causes
• Delineation of top infertility drugs by region
• Comprehensive company profiles of market leaders in drugs and devices
• Patent status of older and newer infertility drugs.

Target Date: July 2012 Report ID: PHM114A Report Author: Manjiri Ghate Price: $4,850.00

This report will provide:

• An overview of the market for asthma and COPD drugs, with descriptions of existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators
• Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Identification of the pipeline of drugs in clinical trials for these indications
• Disease overview
• Discussion of the industry structure and competitive analysis, including tiers of competition, regulatory aspects, competitive factors, market unmet needs, challenges, and trends
• In-depth analyses of current drug classes as well as a profiles of major drugs
• Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development
• Comprehensive company profiles of major players.

Target Date: July 2012 Report ID: PHM059B Report Author: Peggy Lehr Price: $4,850.00

This report will provide:

• An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
• Analyses of global market trends, with data from 2010, estimates for 2011, and projections of compound annual growth rates (CAGRs) through 2016
• Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
• Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
• Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
• Evaluation of prostate cancer treatment products by geography, race, and category
• Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
• Comprehensive company profiles.

Target Date: August 2012 Report ID: PHM113A Report Author: Usha Nagavarapu Price: $4,850.00

highlights to come

highlights to come

Target Date: August 2012 Report ID: PHM117A Report Author: Shalini Shahani Dewan Price: $4,850.00

highlights to come

highlights to come

Target Date: August 2012 Report ID: PHM118A Report Author: Shalini Shahani Dewan Price: $4,850.00

*

Target Date: September 2012 Report ID: PHM045C Report Author: Kevin Gainer Price: $4,850.00

highlights to come

highlights to come

Target Date: September 2012 Report ID: PHM116A Report Author: Usha Nagavarapu Price: $4,850.00